By Dennis Ford, Founder & CEO, Life Science Nation (LSN)
Across Life Science Nation (LSN)’s interconnected network, from the Investor & Licensing Partner Database and RESI Conference Series to LSN Labs, 90 companies have publicly disclosed raising capital or signing licensing deals sourced directly through LSN. LSN has been collecting this disclosed data and, after reaching 90 deals, wanted to extrapolate the compelling metrics behind the LSN engine that facilitated the deals, known as the LSN Ecosystem.
Together, they’ve secured $1.29 billion in verified funding. When factoring in the broader global community of 9,000+ startups that have engaged with LSN tools and programs and gone through the RESI turnstiles, the estimated impact reaches $6.4 billion. This isn’t modeled data; these are real companies, real partners, and real outcomes. It’s proof that structured global partnering delivers measurable success.
A Marketplace That Works — and Scales
At first glance, the dataset lists 90 companies and 52 investors. On closer inspection, that ratio reflects how healthy marketplaces behave. Each transaction represents multiple funding relationships, roughly 100 to 150 discrete deals in total, many of which are undisclosed but very much real.
- For startups, closing $1.29 billion through LSN-facilitated partnerships signals one of the strongest verified conversion rates in early-stage life sciences.
- For investors, repeat participation by six global funds, including corporate venture, pharma, and family offices, demonstrates a growing cycle of trust and sourcing efficiency within LSN’s ecosystem.
This is not a collection of introductions; it’s a living marketplace where structure, data, and discipline transform intro meetings into ongoing dialogue, building relationships that ultimately lead to transactions.
Where the Money Moves: The Four Domains (4Ds)
| SECTOR | DISCLOSED FUNDING ($) | % SHARE | COMMENT |
| Drugs (Therapeutics) | 1,106,490,000 | 83% | Core growth engine for global biotech |
| Devices (Medtech) | 120,820,000 | 9% | Strategic investments and exits rising |
| Diagnostics & Tools | 111,330,000 | 8% | A precision frontier gaining traction |
| Digital Health | Emerging (<1%) | — | Expanding rapidly as AI matures and the software moves adroitly |
Therapeutics dominate the dollars, but the deal flow is distributed, indicating a balanced and resilient early-stage market that spans drugs, devices, diagnostics, and digital health alike.
Even Distribution, Uneven Costs
It’s no surprise that therapeutics absorb most of the capital; drug development is costly and front-loaded. A single preclinical or IND-enabling round can match the combined raises of multiple device or diagnostics startups. But when you look at deal volume, not just deal size, the picture changes. The 90 funded companies are evenly distributed across the 4Ds:
| SECTOR | COMPANIES FUNDED | SHARE OF TOTAL |
| Drugs (Therapeutics) | 31 | 34% |
| Diagnostics & Tools | 26 | 29% |
| Devices (Medtech) | 23 | 26% |
| Digital Health | 10 | 11% |
The big money may flow into drugs, but the deals are happening across all four domains. That balance defines a healthy market, diversified, dynamic, and alive.
Average Deal Size Across the 4Ds
| SECTOR | AVERAGE RAISE PER COMPANY ($) | INSIGHT |
| Drugs (Therapeutics) | $35.7 million | Reflects the high capital intensity of preclinical and early clinical development |
| Devices (Medtech) | $5.3 million | Medtech investors focus on de-risked prototypes and regulatory progress |
| Diagnostics & Tools | $4.3 million | Enabling and precision technologies attract steady, mid-range funding |
| Digital Health | >$3 million | Early but fast-growing; deal sizes expected to rise with data maturity |
These numbers capture a simple truth: Drug rounds dominate in size, but early-stage innovation thrives across every domain. The LSN ecosystem delivers results across all four, not just where the biggest checks are written.
The Signal: Efficiency Is the New Advantage
As global capital tightens, efficiency wins. With RESI London (Dec 2025) and RESI JPM (Jan 2026) approaching, startups and investors alike are leaning into systems that don’t just connect, they convert. LSN’s rhythm of data, readiness, and disciplined outreach has become the commercialization backbone for early-stage life sciences worldwide. “At RESI, we don’t chase headlines; we measure outcomes. The companies and investors in this dataset are the proof.”
Join the Momentum. Be Part of the Data.
The next cycle begins now. Don’t miss your chance to access the world’s most effective life science partnering platform.
Registration now open:
- RESI London 2025 (Dec. 4, 8&9) – [Register]
- RESI JPM 2026 (Jan.12-14, 19&20)– [Register]
- RESI Europe 2026 (March 23-25) – [Register]
JPM is creeping up on you once again, and you still don’t have an event planned. All the good venues are gone and all you’re left with are subprime ones or those with sky-high prices. Why not work with us to plan your best event or partnering table rental at the centrally located Marriott Marquis? 
Next Phase Newsletter 